Adenosquamous carcinoma of the pancreas: Molecular characterization of 23 patients along with a literature review

Table 1 Frequency of malignant exocrine pancreatic neoplasms

Frequency of malignant exocrine pancreatic neoplasms
Histological subtype	Frequency
Adenocarcinoma	85%
Mucinous cyst adenocarcinoma	2%
Adenosquamous	0.38%-10%
Undifferentiated/anaplastic carcinoma	< 1%
Intraductal papillary mucinous carcinoma	3%
Acinar cell carcinoma	< 1%
Rare subtypes	4%

Rare subtypes include signet ring cell carcinoma, giant cell tumor, cystadenocarcinoma, pancreatoblastoma, spindle cell carcinoma.

Table 2 Incidence of adenosquamous carcinoma of the pancreas

Pancreatic cancer specimens	No. (%) of ASCP	Ref.
15185	81 (0.05)	[2]
5075	46 (0.9)	[6]
264	10 (3.8)	[8]
391	13 (3.4)	[9]
80	8 (10)	[10]
202	6 (3)	[11]
3651	45 (1.2)	[12]
45693	415 (0.9)	[13]
237	7 (2.9)	[14]
406	14 (4)	[15]
1025	46 (4.5)	[16]
24604	95 (0.38)	[17]
635	20 (3.1)	[18]
8372	25 (0.3)	[19]
234	7 (2.9)	[20]

ASCP: Adenosquamous carcinoma of the pancreas.

Table 3 Molecular profiling of patients with adenosquamous carcinoma of the pancreas: Immunohistochemistry analysis

IHC analysis percent positive expression (positive/number examined)
MRP1	BCRP	MGMT	TOP2A	TUBB3	PTEN	SPARC	TOPO1	RRM1	cMET	TLE3	TS	ERCC1	PGP	C-kit	PR	AR	ER	Her2
80 (8/10)	80 (4/5)	76 (16/21)	78 (14/18)	38 (3/8)	41 (9/22)	39 (9/23)	38 (8/21)	43 (9/21)	33 (4/12)	42 (5/12)	38 (8/21)	31 (4/13)	11 (2/18)	10 (1/10)	5 (1/21)	0 (0/21)	5 (1/21)	0 (0/22)

IHC: Immunohistochemistry.

Table 4 Molecular profiling of patients with adenosquamous carcinoma of the pancreas: Fluorescence in situ hybridization/chromogenic in situ hybridization analysis

FISH/CISH percent positive expression (positive/number examined)
cMET	EGFR	Her2	TOP2A	ALK
9 (1/11)	0 (0/6)	0 (0/12)	0 (0/2)	0 (0/1)

FISH: Fluorescence in situ hybridization; CISH: Chromogenic in situ hybridization.

Table 5 Molecular profiling of patients with adenosquamous carcinoma of the pancreas: Mutated gene analysis (either sanger or next generation sequencing)

Mutated genes percent positive (number found/examined)
cMET	KRAS	TP53	BRAF	NRAS	SMAD4	cKIT	PIK3CA	EGFR
13 (1/13)	100 (16/16)	50 (4/8)	0 (0/9)	0 (0/9)	25 (2/8)	0 (0/9)	0 (0/11)	0 (0/10)